scholarly journals Gastrointestinal Stromal Tumor (GIST) and Synchronous Intra-Abdominal Liposarcoma: A Report of Two Rare Cases and Literature Review

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Alexandros Diamantis ◽  
Athina A. Samara ◽  
Ioannis Baloyiannis ◽  
Dimitrios Symeonidis ◽  
Andreas-Marios Diamantis ◽  
...  
Keyword(s):  
Literature Review ◽  
Gastrointestinal Stromal Tumor ◽  
Current Literature ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumor ◽  
R0 Resection ◽  
Gastric Gist ◽  
Stromal Tumors ◽  
Retroperitoneal Liposarcoma ◽  
Electronic Search

Introduction. Gastrointestinal stromal tumors (GISTs) quite frequently occur synchronously with other malignancies, with most cases being adenocarcinomas. GISTs and liposarcomas are both of mesenchymal origin, and their coexistence is extremely rare. Methods. We conducted a review of the current literature regarding the synchronous occurrence of GISTs and intra-abdominal liposarcomas. An electronic search of the literature was undertaken using MEDLINE (database provider PubMed). Furthermore, we present the first described case of an 86-year-old male with a GIST and synchronous liposarcoma, both located in the stomach, as well as a 66-year-old male with a gastric GIST and concurrent retroperitoneal liposarcoma. Results. A total of 5 cases of synchronous GIST and intra-abdominal liposarcoma have been reported in the literature to date, with the most recent cases included in the present study. Conclusion. Further research is required to explain any possible correlation in the coexistence of these different neoplasms of the same origin. Meanwhile, R0 resection of both tumors remains the treatment of choice.

scholarly journals Extra-Gastrointestinal retroperitoneal giant stromal tumor complicated with intra-tumoral hemorrhage: case report and literature review

2015 ◽  
Vol 21 (1) ◽  
pp. 1-6
Author(s):  
B.A. Suciu ◽  
V. Bud ◽  
Doina Milutin ◽  
Ioana Halmaciu ◽  
C. Constantin ◽  
...  
Keyword(s):  
Case Report ◽  
Gastrointestinal Tract ◽  
Literature Review ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumor ◽  
Stromal Tumors ◽  
Pathological Characteristics ◽  
Mesenchymal Origin ◽  
Extragastrointestinal Stromal Tumor

Abstract Gastrointestinal stromal tumors are an uncommon sarcomas with mesenchymal origin that arises in the gastrointestinal tract. Recently, most of the published reports describe such tumors located outside of the gastrointestinal tract, with similar pathological characteristics and are named extra-gastrointestinal stromal tumors. We report the case of a patient suffering for a giant retroperitoneal extra-gastrointestinal stromal tumor, complicated with intra-tumoral hemorrhage. The particularity of this case is the presence of the intra-tumoral hemorrhage in a retroperitoneal extragastrointestinal stromal tumor that grew rapidly in volume (in 1 week).

scholarly journals Gastric schwannoma: a benign tumor often misdiagnosed as gastrointestinal stromal tumor

2015 ◽  
Vol 5 (3) ◽  
Author(s):  
Apurva S. Shah ◽  
Pravin M. Rathi ◽  
Vaibhav S. Somani ◽  
Astha M. Mulani
Keyword(s):  
Differential Diagnosis ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Rare Case ◽  
Benign Tumor ◽  
Stromal Tumor ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Gastric Schwannoma ◽  
Gastric Mass

Gastric schwannomas are rare mesenchymal tumors that arise from the nerve plexus of gut wall. They present with nonspecific symptoms and are often detected incidentally. Preoperative investigation is not pathognomic and many are therefore misdiagnosed as gastrointestinal stromal tumors. We report a rare case of a 37-year old woman who underwent laparotomy for complex bilateral ovarian cyst with resection of gastric-gastrointestinal stromal tumor preoperatively, but confirmed to have a gastric schwannomas postoperatively. This case underscores the differential diagnosis of submucosal, exophytic gastric mass as schwannoma.

scholarly journals Duodenal Gastrointestinal Stromal Tumor: A Rare Cause for Recurrent Anaemia

1970 ◽  
Vol 18 (1) ◽  
pp. 85-87
Author(s):  
H Aftab ◽  
J Alam ◽  
S Parveen ◽  
MZ Hossain ◽  
F Ahmed ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Clinical Presentation ◽  
Stromal Tumor ◽  
Stromal Tumors ◽  
Rare Neoplasm

Gastrointestinal Stromal tumors are rare neoplasm that account for < 1% of all GI malignancies. GISTs arise rarely in the duodenum and clinical presentation is variable. This report describes a case of a GIST arising from the duodenum resulting in recurrent anaemia. DOI: 10.3329/jdmc.v18i1.6314 J Dhaka Med Coll. 2009; 18(1) : 85-87

scholarly journals Primary Extra-gastrointestinal Stromal Tumor of Retroperitoneum

2012 ◽  
Vol 6 ◽  
pp. CMO.S9180 ◽  
Author(s):  
Claudio Casella ◽  
Vincenzo Villanacci ◽  
Filippo D'adda ◽  
Manuela Codazzi ◽  
Bruno Salerni
Keyword(s):  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumor ◽  
Radiological Evaluation ◽  
Retroperitoneal Mass ◽  
Stromal Tumors ◽  
Mesenchymal Neoplasms ◽  
Paravertebral Region ◽  
Histology And Immunohistochemistry

Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. More rarely neoplasms with histology and immunohistochemistry similar to GISTs may occur outside the gastrointestinal tract (omentum, mesentery and retroperitoneum) and are so-called Extra-gastrointestinal Stromal Tumors (EGISTs). EGISTs arising in the retroperitoneum are extremely rare: to date, only 58 cases have been reported in the literature. Case Report We herein report a case of a primary EGIST of the retroperitoneum surgically treated. The pre-operative radiological evaluation showed a retroperitoneal mass, placed in left paravertebral region. Results Morphological and immunohistochemical features led to a diagnosis of extra-gastrointestinal stromal tumor (intermediate-low risk form). Conclusions As a result of the rarity of reports of primary EGISTs of retroperitoneum we need to analyze the data of reported cases in order to gain a better understanding about the pathogenesis, prognosis and optimal treatment of this disease.

Large Omental Metastases of a Gastrointestinal Stromal Tumor

Medicina ◽  
2011 ◽  
Vol 47 (11) ◽  
pp. 86
Author(s):  
Povilas Ignatavičius ◽  
Tomas Petraitis ◽  
Žilvinas Saladžinskas ◽  
Lilija Butkevičienė ◽  
Kristina Žvinienė
Keyword(s):  
Case Report ◽  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Interstitial Cells Of Cajal ◽  
Metastatic Tumor ◽  
Stromal Tumor ◽  
Mesenchymal Tumors ◽  
Stromal Tumors ◽  
Cells Of Cajal

Gastrointestinal stromal tumors are rare tumors, originating from the interstitial cells of Cajal. They are the most common mesenchymal tumors of the gastrointestinal tract. Metastatic tumor is treated with imatinib mesylate. A case of large metastases of a gastrointestinal stromal tumor to the omentum, diagnosis and treatment principles are presented in this case report.

scholarly journals A Malignant Gastrointestinal Stromal Tumor of the Gallbladder Immunoreactive for PDGFRA and Negative for CD 117 Antigen (c-KIT)

HPB Surgery ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Athanasios Petrou ◽  
Pari Alexandrou ◽  
Alexandros Papalambros ◽  
Angelica Saetta ◽  
Paraskevi Fragkou ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Growth Factor Receptor ◽  
Stromal Tumor ◽  
Platelet Derived Growth Factor ◽  
Stromal Tumors ◽  
Cd 117 ◽  
Factor Receptor Alpha ◽  
Malignant Gists ◽  
First Time

Gastrointestinal stromal tumors (GISTs) compose the largest category of well-recognized nonepithelial neoplasms of the gastrointestinal tract (GI). GISTs of the gallbladder are extremely rare tumors. Only four malignant, two benign and one GIST-like tumor of the gall bladder have ever been described. The four malignant GISTs were all positive for CD 117 antigen (c-kit). We present for the first time a malignant gastrointestinal stromal tumor of the gallbladder, immunoreactive for platelet-derived growth factor receptor alpha (PDGFRA) and negative for CD 117 antigen (c-KIT).

A multinational phase II clinical trial of neoadjuvant imatinib for large gastrointestinal stromal tumor of the stomach.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 130-130
Author(s):  
Han-Kwang Yang ◽  
Yukinori Kurokawa ◽  
Min-Hee Ryu ◽  
Haruhiko Cho ◽  
Sook Ryun Park ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Gastrointestinal Stromal Tumor ◽  
Neoadjuvant Treatment ◽  
Stromal Tumor ◽  
Maximal Response ◽  
R0 Resection ◽  
Gastric Gist ◽  
Efficacy And Safety ◽  
Resection Rate

130 Background: Neoadjuvant therapy is expected to reduce the risk of primary surgery, such as rupture of the tumor, hemorrhage, and multi-visceral resection, and to improve survivals for patients with a large gastric gastrointestinal stromal tumor (GIST). This study aims to evaluate the efficacy and safety of neoadjuvant imatinib therapy for a large gastric GIST. Methods: Patients with gastric GIST, which is 10cm or larger and without metastasis, received neoadjuvant imatinib (400mg/day) for 6 months, and up to 9 months if maximal response is expected. Postoperative adjuvant imatinib was prescribed for at least 1 year and up to 3 years according to adjuvant treatment guideline. The primary endpoint was complete (R0) resection rate. A primary analysis were performed by the time all the operations were finished, to examine the efficacy and safety of the neoadjuvant treatment. Results: Between Feb 2010 and Sep 2014, 55 patients were enrolled in Japan and Korea. One patient with a jejunal GIST and one patient with PDGFRA-18 D842V mutation were excluded from analysis. Mean tumor diameter was 12cm (10-23). 86.8% of patients (46/53) completed neoadjuvant treatment. Dose reduction of imatinib was performed in 26.4% (14/53). The most frequent Grade 3 or 4 adverse events were G3 rash (5/53, 9.4%) and G3/4 neutropenia (4/53, 7.5%). Disease control rate (PR+SD) and response rate (PR) of neoadjuvant imatinib was 100% and 62.3% by RECIST, and 100% and 98.1% by Choi criteria, respectively. There was no case of CR or PD. 50 patients underwent operation, and R0 resection rate was 90.6% (n = 48, 95% CI 79.3% - 96.9%), which was significantly higher than the threshold value of 70% (p < 0.001). Combined resection of other organs (except gall bladder) was performed in 24.5% (n = 13), and 83.0% of patients (n = 44) could preserve ≥ 50% of the stomach. Postoperative complication occurred in 18.0% (9/50). Conclusions: Neoadjuvant imatinib treatment is effective and safe treatment option for a large primary GIST allowing high R0 resection rate with acceptable incidence of adverse events and postoperative complications. Clinical trial information: UMIN000003114.

scholarly journals Primary-multiple gastrointestinal stromal tumor of the stomach

2020 ◽  
Vol 24 (3-6) ◽  
pp. 84-88
Author(s):  
S. D. Fokeev ◽  
S. U. Kapitulin ◽  
E. S. Kazantseva ◽  
U. G. Belokrilova
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Immunohistochemical Study ◽  
Anterior Wall ◽  
Stromal Tumor ◽  
Stromal Tumors ◽  
Radical Treatment ◽  
Large Size

The result of the radical treatment for multiple gastrointestinal stromal tumors of large size (GIST) coming from the anterior wall of the stomach has been represented. Conducted researches at the prehospital stage are not indicated on the GIST of the stomach. The GIST presence was confirmed by the immunohistochemical study.

scholarly journals Giant gastrointestinal stromal tumor of ileum: the gist of GIST: a case report

2017 ◽  
Vol 4 (3) ◽  
pp. 1096
Author(s):  
M. S. Ray ◽  
B. S. Deepak
Keyword(s):  
Case Report ◽  
Gastrointestinal Tract ◽  
Gastrointestinal Stromal Tumor ◽  
Gastrointestinal Stromal Tumors ◽  
Standard Of Care ◽  
Clinical Situation ◽  
Stromal Tumor ◽  
Curative Therapy ◽  
Stromal Tumors ◽  
Mesenchymal Neoplasms

Gastrointestinal stromal tumors (GIST) are relatively rare pathology as compared with other mitotic lesions of GIT. However, GIST is the most common mesenchymal neoplasms of the gastrointestinal tract. Biopsy of the lesion and Immuno-Histo-Chemistry (IHC) for CD117 confirms the diagnosis. Surgery remains the standard of care and only potentially curative therapy for patients with primary, resectable, localized gastrointestinal stromal tumor. However, chemotherapy with Imatinib is added in neoadjuvant or adjuvant form according to clinical situation, and histopathological status of the lesion.

scholarly journals Low-molecular-weight fibroblast growth factor-2 — a viable prognostic factor for gastric gastrointestinal stromal tumors

2021 ◽  
Vol 102 (3) ◽  
pp. 313-321
Author(s):  
E G Mikheeva ◽  
A M Aukhadieva ◽  
A G Sabirov ◽  
S V Boichuk
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Gastrointestinal Stromal Tumor ◽  
Fibroblast Growth Factor ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumor ◽  
Fibroblast Growth Factor 2 ◽  
Low Molecular Weight ◽  
Fibroblast Growth ◽  
Stromal Tumors

Aim. To examine the expression of fibroblast growth factor-2 and its isoforms in gastrointestinal stromal tumors and assess the prognostic value of this marker. Methods. The study included 44 patients with gastric gastrointestinal stromal tumors of the stomach who were prescribed surgical or combined treatment with the targeted drug imatinib (imatinib mesylate). Immunohistochemistry (IHC)-staining and immunoblotting with monoclonal antibodies were used to assess the expression of FGF-2. Statistical analysis for differences in clinical and morphological parameters was performed by using Students, MannWhitneyWilcoxon and Fishers tests. Differences were considered significant at p 0.05. Results. Fibroblast growth factor-2 expression was assessed in tumor tissues in 39 out of 44 analyzed patients. The frequency of fibroblast growth factor-2 expression in the observed patients was 84.6% (33/39). The moderate and strong fibroblast growth factor-2 expression was detected in 21 (53.8%) patients with gastric gastrointestinal stromal tumors. High expression of low-molecular weight (18 kDa) fibroblast growth factor-2 isoform was found in all tumor samples from patients with high-risk gastrointestinal stromal tumor (prognostic group 6) (p=0.039), which indicated the active secretion of this ligand by its signalling pathway in the cancer cells. Patients with high levels of low‐molecular‐weight fibroblast growth factor-2 showed a higher level of Ki-67 proliferative activity (р=0.013) and tumor size (р=0.0017). Patients with increased expression of the low molecular weight isoform of fibroblast growth factor-2 in gastric gastrointestinal stromal tumor had a higher risk of recurrence, as well as larger tumor size and proliferative activity compared with patients without expression of this isoform. The level of fibroblast growth factor-2 expression in tumor samples, determined by immunohistochemistry-staining, increases after initiation of imatinib to based therapy, which may indicate the formation of resistance to this targeted drug and the progression of the disease. Conclusion. The results of the study suggest that FGF-2 might be an independent prognostic marker of gastric gastrointestinal stromal tumor and a viable therapeutic target.

Sign in / Sign up

Export Citation Format

Share Document